Peroxisome Proliferator-activated Receptor (PPAR) Gene Profiling Uncovers Insulin-like Growth Factor-1 as a PPARα Target Gene in Cardioprotection*

Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor family of ligand-activated transcription factors and consist of the three isoforms, PPARα, PPARβ/δ, and PPARγ. Considerable evidence indicates the importance of PPARs in cardiovascular lipid homeostasis and diabetes, yet the isoform-dependent cardiac target genes remain unknown. Here, we constructed murine ventricular clones allowing stable expression of siRNAs to achieve specifically knockdown for each of the PPAR isoforms. By combining gene profiling and computational peroxisome proliferator response element analysis following PPAR isoform activation in normal versus PPAR isoform-deficient cardiomyocyte-like cells, we have, for the first time, determined PPAR isoform-specific endogenous target genes in the heart. Electromobility shift and chromatin immunoprecipitation assays demonstrated the existence of an evolutionary conserved peroxisome proliferator response element consensus-binding site in an insulin-like growth factor-1 (igf-1) enhancer. In line, Wy-14643-mediated PPARα activation in the wild-type mouse heart resulted in up-regulation of igf-1 transcript abundance and provided protection against cardiomyocyte apoptosis following ischemia/reperfusion or biomechanical stress. Taken together, these data confirm igf-1 as an in vivo target of PPARα and the involvement of a PPARα/IGF-1 signaling pathway in the protection of cardiomyocytes under ischemic and hemodynamic loading conditions.

[1]  Bernd Zetsche,et al.  Local Atrial Natriuretic Peptide Signaling Prevents Hypertensive Cardiac Hypertrophy in Endothelial Nitric-oxide Synthase-deficient Mice* , 2005, Journal of Biological Chemistry.

[2]  A. M. Lefer,et al.  Cardioprotective effect of insulin-like growth factor I in myocardial ischemia followed by reperfusion. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[3]  L. D. de Windt,et al.  Activation of PPARδ inhibits cardiac fibroblast proliferation and the transdifferentiation into myofibroblasts , 2007 .

[4]  T. Casavant,et al.  Gene expression profiling of potential PPARγ target genes in mouse aorta , 2004 .

[5]  Atsushi Ono,et al.  Profiling of gene expression in rat liver and rat primary cultured hepatocytes treated with peroxisome proliferators. , 2006, The Journal of toxicological sciences.

[6]  C. Yeh,et al.  Inhibition of NF-κB Activation Can Attenuate Ischemia/Reperfusion-Induced Contractility Impairment Via Decreasing Cardiomyocytic Proinflammatory Gene Up-Regulation and Matrix Metalloproteinase Expression , 2005, Journal of cardiovascular pharmacology.

[7]  M. Rao,et al.  Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver. , 1993, The Journal of biological chemistry.

[8]  Michael D. Schneider,et al.  Cardiac peroxisome proliferator-activated receptor gamma is essential in protecting cardiomyocytes from oxidative damage. , 2007, Cardiovascular research.

[9]  G. FitzGerald,et al.  Oxidative stress and cardiovascular injury: Part II: animal and human studies. , 2003, Circulation.

[10]  G. Dorn,et al.  Decompensation of cardiac hypertrophy: cellular mechanisms and novel therapeutic targets. , 2007, Physiology.

[11]  K. Kinzler,et al.  PPARδ Is an APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs , 1999, Cell.

[12]  M. Chandler,et al.  Effects of chronic activation of peroxisome proliferator-activated receptor-alpha or high-fat feeding in a rat infarct model of heart failure. , 2006, American journal of physiology. Heart and circulatory physiology.

[13]  Paul A. Overbeek,et al.  TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice , 2000, Nature Medicine.

[14]  Danielle G. Lemay,et al.  Genome-wide identification of peroxisome proliferator response elements using integrated computational genomics s⃞ Published, JLR Papers in Press, April 3, 2006. , 2006, Journal of Lipid Research.

[15]  D. Kelly,et al.  The PPAR trio: regulators of myocardial energy metabolism in health and disease. , 2008, Journal of molecular and cellular cardiology.

[16]  Vincenzo Lionetti,et al.  Chronic Activation of Peroxisome Proliferator-Activated Receptor-α with Fenofibrate Prevents Alterations in Cardiac Metabolic Phenotype without Changing the Onset of Decompensation in Pacing-Induced Heart Failure , 2007, Journal of Pharmacology and Experimental Therapeutics.

[17]  E. Olson,et al.  Conditional Expression of SV40 T-antigen in Mouse Cardiomyocytes Facilitates an Inducible Switch from Proliferation to Differentiation* 210 , 2003, The Journal of Biological Chemistry.

[18]  P. Doevendans,et al.  Downregulation of Apoptosis-Inducing Factor in Harlequin Mutant Mice Sensitizes the Myocardium to Oxidative Stress–Related Cell Death and Pressure Overload–Induced Decompensation , 2005, Circulation research.

[19]  Arnaud Pillon,et al.  Differential responses of PPARα, PPARδ, and PPARγ reporter cell lines to selective PPAR synthetic ligands , 2005 .

[20]  M. Bilsen,et al.  Metabolic remodelling of the failing heart: beneficial or detrimental? , 2008 .

[21]  G. J. van der Vusse,et al.  Peroxisome proliferator‐activated receptors and inflammation: take it to heart , 2007, Acta physiologica.

[22]  B. Spiegelman,et al.  Differential activation of adipogenesis by multiple PPAR isoforms. , 1996, Genes & development.

[23]  X. Wehrens,et al.  NFATc2 Is a Necessary Mediator of Calcineurin-dependent Cardiac Hypertrophy and Heart Failure* , 2008, Journal of Biological Chemistry.

[24]  H. Taegtmeyer,et al.  Reactivation of Peroxisome Proliferator-activated Receptor α Is Associated with Contractile Dysfunction in Hypertrophied Rat Heart* , 2001, The Journal of Biological Chemistry.

[25]  J. Comella,et al.  Activation of Phosphatidylinositol 3‐Kinase, but Not Extracellular‐Regulated Kinases, Is Necessary to Mediate Brain‐Derived Neurotrophic Factor‐Induced Motoneuron Survival , 1999, Journal of neurochemistry.

[26]  G. Reach,et al.  PPAR-α–Null Mice Are Protected From High-Fat Diet–Induced Insulin Resistance , 2001 .

[27]  P. Libby,et al.  PPARα Activators Inhibit Cytokine-Induced Vascular Cell Adhesion Molecule-1 Expression in Human Endothelial Cells , 1999 .

[28]  J. Ross,et al.  Loss of a gp130 Cardiac Muscle Cell Survival Pathway Is a Critical Event in the Onset of Heart Failure during Biomechanical Stress , 1999, Cell.

[29]  A. M. Lefer,et al.  Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. , 1995, Circulation.

[30]  Lei Wang,et al.  Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor I. , 1998, Circulation research.

[31]  R. Evans,et al.  Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[32]  G. Condorelli,et al.  MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling , 2010, Nature Cell Biology.

[33]  P. Anversa,et al.  Insulin-like growth factor-1 attenuates the detrimental impact of nonocclusive coronary artery constriction on the heart. , 1999, Circulation research.

[34]  Xianlin Han,et al.  A critical role for PPARα-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: Modulation by dietary fat content , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[35]  J. Ward,et al.  Growth, Adipose, Brain, and Skin Alterations Resulting from Targeted Disruption of the Mouse Peroxisome Proliferator-Activated Receptor β(δ) , 2000, Molecular and Cellular Biology.

[36]  D. Haro,et al.  Functional interaction between peroxisome proliferator-activated receptors-α and Mef-2C on human carnitine palmitoyltransferase 1β (CPT1β) gene activation , 2004 .

[37]  Xianlin Han,et al.  Nuclear receptors PPARβ/δ and PPARα direct distinct metabolic regulatory programs in the mouse heart , 2007 .

[38]  P. Doevendans,et al.  Myocyte apoptosis in heart failure. , 2005, Cardiovascular research.

[39]  G. J. van der Vusse,et al.  Peroxisome Proliferator-Activated Receptor (PPAR) &agr; and PPAR&bgr;/&dgr;, but not PPAR&ggr;, Modulate the Expression of Genes Involved in Cardiac Lipid Metabolism , 2003, Circulation research.

[40]  H. Vidal,et al.  The Regulation of Uncoupling Protein-2 Gene Expression by ω-6 Polyunsaturated Fatty Acids in Human Skeletal Muscle Cells Involves Multiple Pathways, Including the Nuclear Receptor Peroxisome Proliferator-activated Receptor β* , 2001, The Journal of Biological Chemistry.

[41]  P. Doevendans,et al.  MEF2 Activates a Genetic Program Promoting Chamber Dilation and Contractile Dysfunction in Calcineurin-Induced Heart Failure , 2006, Circulation.

[42]  Michael D. Schneider,et al.  Cardiomyocyte-restricted peroxisome proliferator-activated receptor-δ deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy , 2004, Nature Medicine.

[43]  P. Doevendans,et al.  Requirement of Nuclear Factor of Activated T-cells in Calcineurin-mediated Cardiomyocyte Hypertrophy* , 2002, The Journal of Biological Chemistry.